hotspot -WSS

hotspot

author：explore 2025-09-29 16:33:08 - browse：7

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Weight loss drug costs may need more research, senator suggests

WSS

Elizabeth Holmes on track for early release from her 11

Hospitals look to new technology to keep health care workers safe

Anthos stroke drug appears safer than common blood thinner

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

New research casts further doubt on a common procedure used with IVF

Study: Pain burden is higher in Black NFL players than white ones

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

After affirmative action ruling, medical educators look to 'holistic review'

Does good food count as health care? Study aims to find out

As demand for Covid shots wanes, Moderna seeks its next success

Beach reads and more: STAT's 2023 summer book list

How to save PrEP access — and even expand it

Gain of function research would be limited under House proposal

What does generative AI mean for health care? We asked experts

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Psychedelics group wrestles with new pharma identity

PBM reforms clear House panel

hotspot

CRISPR pioneers react to Casgevy, first gene

Morphosys mixed study results for blood cancer drug

Oak trusses raised to roof of fire

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Poor hospice wound care hurts patients and families

Astellas still sees hope in its gene therapy after four deaths

entertainment

knowledge

explore

focus